Purple Biotech Ltd. · TASE:PPBT
Purple Biotech — Kitov Pharmaceuticals Holdings — Investor Presentation (January 2017)
13 slides from Purple Biotech's investor presentation, Jan 23, 2017

Slide 1: TyrNovo's NT 219: A New Concept in Cancer Therapy
Thank you Streamlined Innovative Drug Development TyrNovo’s NT 219 A New Concept in Cancer Therapy January 23 , 2017 © 2017 Proprietary and Confidential

Slide 2: Forward Looking Statements and Kitov's Safe Harbor Statement
Forward Looking Statements and Kitov’s Safe Harbor Statement This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction . Certain statements in this presentation are forward - looking statements within the meaning of the safe harbor provisions of the

Slide 3: Agenda
ϯ Agenda • TyrNovo’s NT 219 : A New Concept in Cancer Therapy o Technology Highlights o Mechanism of Action o Patient Derived Xenograft Results o Business Opportunity • TyrNovo Transaction Highlights • KIT - 302 Recent Achievements and Milestones • Kitov’s Strategy

Slide 4: NT 219 Technology Highlights
ϰ NT 219 - Technology Highlights • NT 219 is a small molecule developed jointly by Alexander Levitzki , Ph.D., (Laureate of the 2005 Wolf Prize in Medicine) a professor at the Hebrew University of Jerusalem and Hadas Reuveni, Ph.D., co - founder and CTO of TyrNovo • NT 219 overcomes drug resistanc

Slide 5: NT 219 Mechanism of Action
NT 219 - Mechanism of Action ϱ • Anti - cancer drugs induce feedback activation of two major pathways, the STAT 3 and the IRS, leading to drug resistance • NT 219 effectively targets these feedback pathways and thereby overcomes drug resistance and extends the positive response to the drugs • Inhi

Slide 6: NT 219 Prevents Acquired Resistance to Erlotinib in Head & Neck Tumors
ϲ Response Erlotinib: Acquired resistance NT 219 prevents resistance to Erlotinib NT 219 : 100 Tumor Regression of Patient - Derived Head & Neck Cancer Implanted in mice (PDX model) Days (n= 8 ) (n= 8 ) (n= 8 ) (n= 8 ) NT 219 Demonstrated to Prevent Acquired Resistance of Head & Neck Tumors to EGF

Slide 7: NT 219 Converted Non-Responding Pancreatic Tumors to Responders
NT 219 Successfully Converted Non - Responding Pancreatic Tumors to Responders to Gemcitabine (Gemzar ® ) Non - Responders Responders Tumor Regression of Patient - Derived Pancreatic Cancer Implanted in mice (PDX model) ϳ

Slide 8: NT 219 Synergistic Immunotherapeutic Effect with Cetuximab
ϴ NT 219 Shown to Have Synergistic I mmunotherapeutic E ffect with Anti - EGFR Ab Cetuximab (Erbitux ®) Initial results demonstrated that NT 219 has promising immunotherapeutic potential PBMCs (patient derived) Three treatments (days 0 , 3 , 10 ) Cetuximab - treated mice Cetuximab+NT 219 - treated

Slide 9: NT 219 Business Opportunity
NT 219 Business Opportunity ϵ * Global Data • NT 219 has the potential to be combined with numerous oncology drugs, and to expand the efficacy duration, target patient population, and patent lifespan of the applicable drugs • Accumulated annual sales of the relevant cancer drugs exceeds $ 6 B • Im

Slide 10: Transaction Highlights
Transaction Highlights ϭϬ • Kitov purchased all shares held by majority shareholder ( 56 %) • Total consideration of $ 3.8 M: o $ 2 M in cash o $ 1.8 M in Kitov shares ( 6.8 % of Kitov issued & outstanding; shares subject to lock - up & standstill) • Possible additional purchase of minority share

Slide 11: KIT-302 Recent Achievements and Milestones
KIT - 302 Recent Achievements and Milestones ϭϭ Q 2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 2016 2017 2018 JUNE Completed initial stability study AUGUST U.S . Patent issued Q 1 ’ 17 Anticipated NDA Submission to FDA Q 1 ’ 18 Expected FDA Clearance for Marketing MAY ▪ Received FDA minutes that support NDA submission

Slide 12: Kitov's Strategy
Kitov’s Strategy ϭϮ x Establish a diverse pipeline that will drive long term value creation for our shareholders x Harness our team’s proven track record in drug development x Leverage the benefits of out - licensing our late - stage / approved drugs (e.g. KIT - 302 ) in order to support pipeline

Slide 13: Thank you
Thank you Streamlined Innovative Drug Development Company Headquarters One Azrieli Center Round Tower 132 Menahem Begin Road Tel Aviv 6701101 , Israel US Medical Research Office 1615 Suter's Lane NW Washington DC 20007 Contact Us Tel : + 972 - 3 - 9333121 Email: Info@kitovpharma.com www.kitovpha
Source: SEC EDGAR · 6-K filed Jan 23, 2017
More decks from Purple Biotech Ltd.
Investor Presentation (August 2026)45 slides · Aug 10, 2026
Investor Presentation (June 2026)45 slides · Jun 23, 2026
Investor Presentation (March 2026)59 slides · Mar 19, 2026
Investor Presentation (January 2026)62 slides · Jan 13, 2026
Investor Presentation (January 2026)59 slides · January 2026
Investor Presentation (November 2025)57 slides · Nov 19, 2025